About Audentes Therapeutics (NASDAQ:BOLD)
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BOLD
CUSIPN/A
Phone415-638-6556
Debt
Debt-to-Equity RatioN/A
Current Ratio7.74%
Quick Ratio7.74%
Price-To-Earnings
Trailing P/E Ratio-11.17
Forward P/E Ratio-11.07
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($5.38) per share
Price / Book-7.06
Profitability
EPS (Most Recent Fiscal Year)($3.40)
Net Income$-90,230,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-52.37%
Miscellaneous
Employees152
Outstanding Shares36,670,000
Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions
What is Audentes Therapeutics' stock symbol?
Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."
How were Audentes Therapeutics' earnings last quarter?
Audentes Therapeutics (NASDAQ:BOLD) issued its quarterly earnings results on Thursday, March, 8th. The biotechnology company reported ($0.82) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.91) by $0.09. View Audentes Therapeutics' Earnings History.
When is Audentes Therapeutics' next earnings date?
What price target have analysts set for BOLD?
10 Wall Street analysts have issued 12-month target prices for Audentes Therapeutics' stock. Their forecasts range from $23.00 to $56.00. On average, they expect Audentes Therapeutics' stock price to reach $35.3750 in the next year. View Analyst Ratings for Audentes Therapeutics.
Who are some of Audentes Therapeutics' key competitors?
Some companies that are related to Audentes Therapeutics include Spark Therapeutics (ONCE), arGEN-X BV (ARGX), China Biologic Products (CBPO), Halozyme (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Repligen (RGEN), Acceleron Pharma (XLRN), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA), DBV Technologies (DBVT) and Iovance Biotherapeutics (IOVA).
Who are Audentes Therapeutics' key executives?
Audentes Therapeutics' management team includes the folowing people:
- Mr. Matthew R. Patterson, Co-Founder, CEO, Pres & Director (Age 46)
- Mr. Thomas P. Soloway, CFO and Sr. VP (Age 51)
- Ms. Natalie C. Holles, Chief Operating Officer and Sr. VP (Age 45)
- Dr. John T. Gray Ph.D., Chief Scientific Officer and Sr. VP (Age 55)
- Ms. Dawn Blessing, VP of Corp. Devel.
When did Audentes Therapeutics IPO?
(BOLD) raised $75 million in an initial public offering on Wednesday, July 20th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Has Audentes Therapeutics been receiving favorable news coverage?
News headlines about BOLD stock have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Audentes Therapeutics earned a news impact score of 0.13 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.01 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Audentes Therapeutics?
Shares of BOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Audentes Therapeutics' stock price today?
One share of BOLD stock can currently be purchased for approximately $37.98.
How big of a company is Audentes Therapeutics?
Audentes Therapeutics has a market capitalization of $1.36 billion. The biotechnology company earns $-90,230,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 152 workers across the globe.
How can I contact Audentes Therapeutics?
Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-638-6556 or via email at [email protected]
MarketBeat Community Rating for Audentes Therapeutics (BOLD)
MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe BOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Audentes Therapeutics (NASDAQ:BOLD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Audentes Therapeutics in the last 12 months. Their average twelve-month price target is $35.3750, suggesting that the stock has a possible downside of 6.86%. The high price target for BOLD is $56.00 and the low price target for BOLD is $23.00. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 2.88 | 2.83 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $35.3750 | $35.3750 | $36.7143 | $26.1667 |
| Price Target Upside: | 6.86% downside | 2.39% downside | 9.11% upside | 4.71% upside |
Audentes Therapeutics (NASDAQ:BOLD) Consensus Price Target History
Audentes Therapeutics (NASDAQ:BOLD) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Audentes Therapeutics (NASDAQ:BOLD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Audentes Therapeutics (NASDAQ BOLD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 47.30%
Institutional Ownership Percentage: 66.96%
Audentes Therapeutics (NASDAQ BOLD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2018 | Matthew R Patterson | CEO | Sell | 700 | $30.01 | $21,007.00 | 700 |  |
| 3/29/2018 | Suyash Prasad | VP | Sell | 7,800 | $30.03 | $234,234.00 | 7,800 | |
| 3/26/2018 | Louis G Lange | Director | Sell | 48,000 | $28.89 | $1,386,720.00 | 414,231 | |
| 3/26/2018 | Suyash Prasad | VP | Sell | 1,900 | $30.00 | $57,000.00 | 1,900 | |
| 3/15/2018 | Mary Newman | SVP | Sell | 10,000 | $30.36 | $303,600.00 | 4,076 | |
| 3/12/2018 | Orbimed Advisors Llc | Major Shareholder | Sell | 156,431 | $34.97 | $5,470,392.07 | | |
| 3/8/2018 | Orbimed Advisors Llc | Major Shareholder | Sell | 58,428 | $34.06 | $1,990,057.68 | | |
| 3/6/2018 | Orbimed Advisors Llc | Major Shareholder | Sell | 433,210 | $35.11 | $15,210,003.10 | | |
| 3/2/2018 | Orbimed Advisors Llc | Major Shareholder | Sell | 421,638 | $35.17 | $14,829,008.46 | | |
| 12/22/2017 | Louis G Lange | Director | Sell | 18,000 | $30.88 | $555,840.00 | | |
| 12/1/2017 | Suyash Prasad | VP | Sell | 8,000 | $28.53 | $228,240.00 | | |
| 11/16/2017 | Mary Newman | SVP | Sell | 10,000 | $26.84 | $268,400.00 | | |
| 10/2/2017 | Matthew R Patterson | CEO | Sell | 25,000 | $27.92 | $698,000.00 | | |
| 9/29/2017 | Louis G Lange | Director | Sell | 11,000 | $28.35 | $311,850.00 | 441,555 | |
| 9/29/2017 | Orbimed Advisors Llc | Major Shareholder | Sell | 672,000 | $28.25 | $18,984,000.00 | | |
| 9/27/2017 | David Nagler | SVP | Sell | 3,750 | $30.00 | $112,500.00 | 3,750 | |
| 9/25/2017 | Louis G Lange | Director | Sell | 18,000 | $28.32 | $509,760.00 | 453,393 | |
| 9/18/2017 | Matthew R Patterson | CEO | Sell | 10,000 | $25.06 | $250,600.00 | 1,542 | |
| 9/15/2017 | David Nagler | SVP | Sell | 3,750 | $25.00 | $93,750.00 | 3,750 | |
| 9/7/2017 | Orbimed Advisors Llc | Major Shareholder | Sell | 5,000 | $22.35 | $111,750.00 | | |
| 9/1/2017 | Suyash Prasad | VP | Sell | 8,000 | $21.44 | $171,520.00 | 8,000 | |
| 8/24/2017 | Mary Newman | SVP | Sell | 10,000 | $20.00 | $200,000.00 | 10,000 | |
| 7/13/2017 | Matthew R Patterson | CEO | Sell | 15,000 | $20.00 | $300,000.00 | | |
| 7/12/2017 | Matthew R Patterson | CEO | Sell | 2,850 | $20.00 | $57,000.00 | | |
| 6/26/2017 | Louis G Lange | Director | Sell | 15,000 | $19.78 | $296,700.00 | 470,799 | |
| 4/24/2017 | 5Am Partners Iii, Llc | Insider | Buy | 172,413 | $14.50 | $2,499,988.50 | | |
| 7/25/2016 | James E Flynn | Insider | Buy | 400,000 | $15.00 | $6,000,000.00 | | |
| 7/25/2016 | Orbimed Advisors Llc | Director | Buy | 33,334 | $15.00 | $500,010.00 | | |
| 7/25/2016 | Versant Ventures Iv, Llc | Major Shareholder | Buy | 35,000 | $15.00 | $525,000.00 | | |
(Data available from 1/1/2013 forward)
Audentes Therapeutics (NASDAQ BOLD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | -$0.81 EPS Expected for Audentes Therapeutics (BOLD) This Quarter
www.americanbankingnews.com - April 24 at 8:08 AM |
| Audentes Therapeutics (BOLD) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 21 at 1:36 AM |
| Comparing Audentes Therapeutics (BOLD) & Biogen (BIIB)
www.americanbankingnews.com - April 11 at 1:17 PM |
| Audentes Therapeutics (BOLD) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM |
 | First Week of BOLD November 16th Options Trading
www.nasdaq.com - April 10 at 4:07 PM |
 | Novartis takeout of AveXis stokes buying in gene therapy players
seekingalpha.com - April 9 at 10:09 AM |
| Audentes Therapeutics (BOLD) Expected to Post Earnings of -$0.81 Per Share
www.americanbankingnews.com - April 7 at 9:55 AM |
| Audentes Therapeutics (BOLD) Coverage Initiated by Analysts at William Blair
www.americanbankingnews.com - April 6 at 10:54 PM |
| Audentes Therapeutics (BOLD) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 5 at 2:14 PM |
| Audentes Therapeutics Inc (BOLD) CEO Matthew R. Patterson Sells 700 Shares
www.americanbankingnews.com - April 4 at 11:37 PM |
| Audentes Therapeutics Inc (BOLD) SVP Sells $303,600.00 in Stock
www.americanbankingnews.com - April 2 at 10:20 PM |
| Audentes Therapeutics (BOLD) Given a $37.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 30 at 3:58 PM |
| Audentes Therapeutics Inc (BOLD) VP Sells $234,234.00 in Stock
www.americanbankingnews.com - March 29 at 10:46 PM |
| Insider Selling: Audentes Therapeutics Inc (BOLD) VP Sells 1,900 Shares of Stock
www.americanbankingnews.com - March 28 at 10:48 PM |
| Insider Selling: Audentes Therapeutics Inc (BOLD) Director Sells 48,000 Shares of Stock
www.americanbankingnews.com - March 28 at 10:31 PM |
| Audentes Therapeutics (BOLD) PT Set at $37.00 by HC Wainwright
www.americanbankingnews.com - March 28 at 8:42 PM |
| Audentes Therapeutics Inc (BOLD) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 27 at 1:39 AM |
| Audentes Therapeutics Inc (BOLD) Expected to Post Earnings of -$0.81 Per Share
www.americanbankingnews.com - March 21 at 12:36 PM |
 | Edited Transcript of BOLD earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 9:48 AM |
| Audentes Therapeutics (BOLD) Downgraded by BidaskClub
www.americanbankingnews.com - March 17 at 7:16 PM |
| Audentes Therapeutics (BOLD) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 13 at 5:48 PM |
| Audentes Therapeutics Inc (BOLD) Major Shareholder Sells $1,990,057.68 in Stock
www.americanbankingnews.com - March 12 at 7:21 PM |
| Audentes Therapeutics Inc (BOLD) Major Shareholder Orbimed Advisors Llc Sells 156,431 Shares
www.americanbankingnews.com - March 12 at 7:21 PM |
| Brokers Offer Predictions for Audentes Therapeutics Inc's FY2022 Earnings (BOLD)
www.americanbankingnews.com - March 12 at 10:02 AM |
| Audentes Therapeutics Inc to Post Q1 2019 Earnings of ($0.94) Per Share, William Blair Forecasts (BOLD)
www.americanbankingnews.com - March 12 at 7:12 AM |
| Audentes Therapeutics' (BOLD) Buy Rating Reaffirmed at William Blair
www.americanbankingnews.com - March 10 at 4:20 PM |
| Wedbush Reiterates Outperform Rating for Audentes Therapeutics (BOLD)
www.americanbankingnews.com - March 9 at 6:13 PM |
| Audentes Therapeutics (BOLD) Rating Reiterated by Cowen
www.americanbankingnews.com - March 9 at 4:54 PM |
| Audentes Therapeutics (BOLD) Releases Earnings Results, Beats Estimates By $0.09 EPS
www.americanbankingnews.com - March 9 at 10:35 AM |
| Audentes Therapeutics (BOLD) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - March 8 at 6:41 PM |
 | Audentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate Update
www.prnewswire.com - March 8 at 4:49 PM |
| Is a Surprise Coming for Audentes Therapeutics (BOLD) This Earnings Season?
finance.yahoo.com - March 7 at 10:04 AM |
| Orbimed Advisors Llc Sells 433,210 Shares of Audentes Therapeutics Inc (BOLD) Stock
www.americanbankingnews.com - March 6 at 6:16 PM |
| Orbimed Advisors Llc Sells 421,638 Shares of Audentes Therapeutics Inc (BOLD) Stock
www.americanbankingnews.com - March 6 at 6:16 PM |
| Audentes Therapeutics to Present at the Cowen 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 9:50 AM |
| -$0.92 EPS Expected for Audentes Therapeutics Inc (BOLD) This Quarter
www.americanbankingnews.com - March 4 at 5:10 AM |
| Ascend Capital LLC Cuts Holdings in Audentes Therapeutics Inc (BOLD)
www.americanbankingnews.com - March 2 at 5:06 AM |
| Audentes Therapeutics Inc (BOLD) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 2 at 1:32 AM |
| Audentes Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update on Thursday, March 8, 2018
finance.yahoo.com - March 1 at 9:34 AM |
| Audentes Therapeutics Inc (BOLD) Shares Bought by Spark Investment Management LLC
www.americanbankingnews.com - February 28 at 5:44 PM |
| Audentes Therapeutics Joins Global Organizations In Recognizing Rare Disease Day® 2018
finance.yahoo.com - February 28 at 9:50 AM |
| Audentes Therapeutics Inc (BOLD) Expected to Post Earnings of -$0.92 Per Share
www.americanbankingnews.com - February 15 at 11:10 AM |
| Audentes Therapeutics (BOLD) Coverage Initiated by Analysts at Mizuho
www.americanbankingnews.com - February 12 at 8:28 PM |
| Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar Syndrome
finance.yahoo.com - February 12 at 8:49 AM |
| Short Interest in Audentes Therapeutics Inc (BOLD) Rises By 71.6%
www.americanbankingnews.com - February 11 at 1:52 AM |
| Audentes Therapeutics (BOLD) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - February 9 at 7:16 PM |
| Audentes Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 9:12 AM |
| Audentes Therapeutics (BOLD) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - February 8 at 12:12 AM |
| Audentes Therapeutics Inc (BOLD) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 5 at 1:28 AM |
 | Gene therapy stocks tank after leading scientist reveals safety concerns; Solid Bioscience down 15%
www.marketwatch.com - January 30 at 4:46 PM |
Audentes Therapeutics (NASDAQ:BOLD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Audentes Therapeutics (NASDAQ:BOLD) Income Statement, Balance Sheet and Cash Flow Statement
Audentes Therapeutics (NASDAQ BOLD) Stock Chart for Thursday, April, 26, 2018
Loading chart…
